The China Mail - Study shows how fast kilos return after ending weight-loss drugs

USD -
AED 3.672501
AFN 64.485622
ALL 81.549749
AMD 361.430444
ANG 1.789785
AOA 917.99947
ARS 1513.248302
AUD 1.433795
AWG 1.8
AZN 1.701095
BAM 1.747405
BBD 2.013572
BDT 123.421934
BGN 1.747831
BHD 0.37766
BIF 2995
BMD 1
BND 1.282034
BOB 11.711836
BRL 5.041198
BSD 0.999772
BTN 95.182957
BWP 13.733399
BYN 3.020865
BYR 19600
BZD 2.010641
CAD 1.421365
CDF 2312.520298
CHF 0.83205
CLF 0.025036
CLP 985.36034
CNY 6.69275
CNH 6.693545
COP 3196.93
CRC 455.660238
CUC 1
CUP 23.993531
CVE 99.404736
CZK 21.771992
DJF 177.719961
DKK 6.68041
DOP 61.249753
DZD 134.533389
EGP 53.067426
ERN 15
ETB 161.130477
EUR 0.89371
FJD 2.26455
FKP 0.754659
GBP 0.756045
GEL 2.597547
GGP 0.754659
GHS 11.664996
GIP 0.754659
GMD 73.999665
GNF 8799.999943
GTQ 7.639869
GYD 209.069102
HKD 7.847785
HNL 26.95013
HRK 6.732599
HTG 130.910423
HUF 325.206958
IDR 17930.35
ILS 3.097596
IMP 0.754659
INR 95.15175
IQD 1513
IRR 1790499.999928
ISK 121.920114
JEP 0.754659
JMD 158.765613
JOD 0.70898
JPY 157.930248
KES 129.779826
KGS 87.450163
KHR 4071.99991
KMF 441.999636
KPW 899.999961
KRW 1341.910271
KWD 0.31165
KYD 0.833099
KZT 451.695332
LAK 22499.999977
LBP 89549.99985
LKR 330.891222
LRD 170.749848
LSL 16.490129
LTL 2.95274
LVL 0.60489
LYD 6.429535
MAD 9.747029
MDL 17.89398
MGA 4499.999495
MKD 55.199462
MMK 2100.02843
MNT 3599.679138
MOP 8.081626
MRU 40.220079
MUR 47.610274
MVR 15.459906
MWK 1741.999788
MXN 18.473045
MYR 4.084099
MZN 63.910111
NAD 16.489766
NGN 1330.050088
NIO 36.849829
NOK 9.49815
NPR 152.293053
NZD 1.784099
OMR 0.384484
PAB 0.999736
PEN 3.430498
PGK 4.45175
PHP 62.907991
PKR 277.035036
PLN 3.906445
PYG 5704.585558
QAR 3.640169
RON 4.768703
RSD 104.962028
RUB 83.624996
RWF 1475
SAR 3.74237
SBD 8.078071
SCR 13.936404
SDG 601.497355
SEK 9.988495
SGD 1.28391
SHP 0.754518
SLE 24.669916
SLL 20969.504398
SOS 571.501784
SRD 37.711972
STD 20697.981008
STN 21.975
SVC 8.747783
SYP 13001.999685
SZL 16.490294
THB 33.633008
TJS 9.227237
TMT 3.5
TND 3.3035
TOP 2.40776
TRY 49.414402
TTD 6.799166
TWD 32.203098
TZS 2630.002993
UAH 44.933885
UGX 4039.293995
UYU 40.187267
UZS 11951.499896
VES 875.701604
VND 25897
VUV 119.372685
WST 2.788609
XAF 586.235332
XAG 0.01792
XAU 0.000242805963
XCD 2.70255
XCG 1.801832
XDR 0.707052
XOF 586.235332
XPF 106.874987
YER 236.200463
ZAR 16.58286
ZMK 9001.197676
ZMW 19.868757
ZWL 321.999592
SSP 5748.524006
MXV 2.086037
  • RYCEF

    0.4000

    19.71

    +2.03%

  • CMSC

    0.0000

    20.4

    0%

  • BTI

    0.4200

    56.05

    +0.75%

  • BP

    0.2800

    44.43

    +0.63%

  • RBGPF

    1.6000

    67

    +2.39%

  • RIO

    -0.1500

    94.41

    -0.16%

  • AZN

    -0.4300

    166.15

    -0.26%

  • GSK

    0.4600

    49.7

    +0.93%

  • BCE

    -0.4100

    20.56

    -1.99%

  • NGG

    -0.2500

    75.24

    -0.33%

  • VOD

    -0.0400

    16.58

    -0.24%

  • RELX

    -0.4500

    33.07

    -1.36%

  • BCC

    -0.5500

    76.59

    -0.72%

  • CMSD

    -0.0300

    20.27

    -0.15%

  • JRI

    -0.2500

    10.77

    -2.32%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: © AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

Y.Parker--ThChM